Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus.

15 Sep 2009

OptiVol for accurate prediction of heart failure

Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.

15 Sep 2009

New generation CPAP mask to aid sleep apnoea patients from ResMed

ResMed, a leading manufacturer of sleep and respiratory medical equipment, today announced that it has introduced a new generation continuous positive airway pressure (CPAP) mask designed to improve the patient experience and compliance. With minimal contact on the face and a sleek design, Swift FX is expected to help sleep apnoea patients overcome issues related to wearing a mask at night and effectively providing them with a good night’s sleep.

From ResMed Corp 15 Sep 2009

Public health policy should stress on reduction in sodium intake

Reducing sodium intake is a major public health priority that must be acted upon by governments and nongovernmental organizations to improve population health, states an article http://www.cmaj.ca/press/cmaj090361.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

15 Sep 2009

New critical illness plan from Colonial Life introduced

A new critical illness plan from Colonial Life & Accident Insurance Company can help many working Americans who may be one serious medical issue away from financial problems. Even with good health insurance, a serious illness, such as a heart attack or stroke, could leave employees on the hook for huge expenses.

15 Sep 2009

Common pain cream could serve as cardiac-protectant during heart attack: Study

New research from the University of Cincinnati (UC) shows that a common, over-the-counter pain salve rubbed on the skin during a heart attack could serve as a cardiac-protectant, preventing or reducing damage to the heart while interventions are administered.

15 Sep 2009

Carotid and cardiac procedures result in higher incidence of post-operative strokes

Among patients undergoing cardiac surgery, post-operative stroke occurred in approximately 2 percent, was not correlated with significant carotid artery narrowing, but was more common among patients who had combined cardiac and carotid procedures, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

14 Sep 2009

Vivakor completes third-party validation testing of its VivaBlend nutraceutical product

Vivakor™, Inc. (OTCBB: VIVK) today announced the results of independent, third-party validation testing of its VivaBlend™ nutraceutical product. VivaBlend is a powerful extract developed by the scientists at Vivakor and is derived from over 18 highly bioactive fruits, vegetables and legumes. Through a proprietary formulation and extraction process, Vivakor scientists have maximized the health benefits of VivaBlend by creating an optimum blend of super-antioxidants and powerful plant phenolics and flavonoids.

14 Sep 2009

Corventis completes enrollment for clinical trials of its MUSIC program

Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company’s MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients).

14 Sep 2009

Innovative stroke treatment device to minimize brain damage

Driven by the emergency-room maxim, "Time is brain," NeuroInterventions, Inc. is prototyping an innovative stroke treatment device designed to speed up the restoration of blood flow and thus minimize brain damage.

14 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009

Research data reveals why women discontinue treatment with current osteoporosis therapies

Amgen Inc. today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR).

14 Sep 2009

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it has begun enrolling patients in the U.S. for a Phase I clinical trial with its unmatched placenta-derived stem cell product, PLX-PAD, the Company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

11 Sep 2009

Cymbalta maintains reduction in pain for patients with chronic low back pain

New data show patients with chronic low back pain on Cymbalta(R) (duloxetine HCl) maintained reductions in pain for 41 weeks. In patients who initially responded to duloxetine, this maintenance of pain reduction was accompanied by further reduction in pain that was statistically significant as measured by the Brief Pain Inventory (BPI) average pain rating.

11 Sep 2009

Newly established Edward Neurosciences Institute to provide advanced stroke care in Chicago

Edward Hospital announced today that it has established the Edward Neurosciences Institute in affiliation with the Northwestern Medical Faculty Foundation to bring the highest level of stroke care in the world to the west and southwest suburbs of Chicago.

11 Sep 2009

ThromboGenics shortlisted for two awards at the Scrip Awards 2009

ThromboGenics NV, a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

Social identity has a positive impact on health and well-being

The quality of a person's social life could have an even greater impact than diet and exercise on their health and well-being. There is growing evidence that being a member of a social group can significantly reduce the risk of conditions like stroke, dementia and even the common cold.

11 Sep 2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that it has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate arimoclomol for the treatment or prevention of neurodegenerative diseases of the central nervous system (CNS).

10 Sep 2009

Stroke rehabilitation technology to improve patients' quality of life

Stroke rehabilitation technology which patients can operate in their own homes while playing computer games, is being developed by academics at the University of Southampton.

10 Sep 2009